Article

Report: Novartis continues efforts to sell off some ophthalmology assets

Author(s):

The company has said it hopes to make the deals to be able to focus on its core areas.

Despite moving forward and reaching out to potential suiters, Novartis could still decide against the sale. (Adobe Stock image)

Despite moving forward and reaching out to potential suiters, Novartis could still decide against the sale. (Adobe Stock image)

Novartis is set to kick off the sale of some of its ophthalmology portfolio assets as it plans to focus more on its core areas, according to a report today by Bloomberg News.

According to reports, the assets on the block include dry eye therapy Xiidra, which had revenues of $487 million in 2022. Bloomberg added the company has engaged an adviser to check interest in the so-called front-of-eye therapies, the report added.

Novartis acquired Xiidra from Takeda Pharmaceutical in 2019 for $3.4 billion in upfront cash plus up to an additional $1.9 billion in milestones.

Moreover, the report cited sources that noted the assets for sale do not include wet age-related macular degeneration therapy Lucentis, which generated about $1.87 billion in revenue last year.

Despite moving forward and reaching out to potential suiters, Novartis could still decide against the sale.

In August, Novartis first announced plans to spin off the Sandoz generics unit as it directed its focus on the development of patented prescription medications.

Last month, Gilbert Ghostine was named chairman-designate of Sandoz.

He will become the chairman of the new board at Sandoz, which is to be formed after its spin-off from Novartis in the second half of 2023, subject to final Novartis Board of Directors and shareholder approvals.

In 2019, Novartis spun off the Alcon eye care business, and in 2021 sold approximately a third of its voting share in Roche.

The company continues to see successes in its ophthalmology pipeline.

In June, Novartis announced that the FDA had approved brolucizumab-dbll 6 mg (BEOVU) for the treatment of diabetic macular edema (DME). The drug had been approved by the European Commission in April.

The company also announced June 20 it purchased Kedalion Therapeutics and its AcuStream technology.

Kedalion Therapeutics is a clinical-stage, venture-funded ophthalmic drug company based in California. The company announced the completion of its Series B funding—led by Novartis—in November 2021.

Novartis did not respond to Bloomberg News for its report.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.